奥泰生物 (688606)

Hangzhou Alltest Biotech Co., Ltd.

KSH

Tags

SSE 580 IndexCSI Dividend IndexPharmaceutical ManufacturingPharmaceuticals and HealthcareGene ConceptPet EconomyHelicobacter PyloriOverseas BusinessBiological ProductsBelow IPO PriceSTAR Market 200 IndexHigh-Performing StocksHepatitis ConceptMargin Trading and Securities LendingAssisted Reproduction

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 7928.09
  • Circulating A-Shares(W): 7928.09
  • Earnings Per Share(RMB): 2.3900
  • Net Assets Per Share(RMB): 49.2146
  • Operating Revenue(W RMB): 63307.66
  • Total Profit(W RMB): 21824.60
  • **Net Profit Attributable to Parent(W RMB) **: 18980.97
  • Net Profit Growth Rate(%): -3.91
  • Weighted Return on Equity(%): 4.8500
  • Operating Cash Flow Per Share(RMB): 1.4440
  • Undistributed Profit Per Share(RMB): 24.0376
  • Capital Reserve Per Share(RMB): 21.3997

2. Main Business

The main business covers:

  • Research, development, production, and sales of in vitro diagnostic reagents

3. Company Basic Information

  • Company Name: Hangzhou AllTest Biotech Co., Ltd.
  • Listing Date: 2021-03-25
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 550, Yin Hai Street, Baiyang Street, Hangzhou Economic and Technological Development Zone, Jianggan District, Hangzhou City, Zhejiang Province
  • Website: https://www.alltests.com.cn
  • Company Profile: The issuer was established as a joint stock company through the overall transformation of AllTest Limited. On October 19, 2017, AllTest Limited held a shareholders' meeting where all shareholders unanimously agreed to act as promoters. Using July 31, 2017, as the restructuring reference date, and based on the audited net asset value of the company of RMB 122,411,449.07 (as per the audit report Zhong Hui Hui Shen [2017] No. 4842 from Zhonghui Accounting Firm (Special General Partnership)), the company was converted into a joint stock company at a ratio of 3.13956:1, resulting in a share capital of 38.99 million shares (par value RMB 1 per share). The registered capital was RMB 38.99 million, and the balance of the net assets after deducting the share capital, RMB 83,421,449.07, was recorded as capital reserve. On October 19, 2017, Tianyuan Asset Appraisal Co., Ltd. issued an Asset Appraisal Report (Tianyuan Ping Bao Zi [2017] No. 0400), appraising the company's overall value as RMB 133.3939 million as of July 31, 2017, which exceeded the company's audited net asset value. On October 19, 2017, all promoters of AllTest Biotech signed the "Sponsor Agreement for the Establishment of Hangzhou AllTest Biotech Co., Ltd.". On November 8, 2017, Zhonghui Accounting Firm (Special General Partnership) issued a Capital Verification Report (Zhong Hui Hui Yan [2017] No. 4843), verifying that the registered capital of the joint stock company, contributed through the net assets of the limited company during the overall restructuring, had been fully paid up as of November 8, 2017. On November 8, 2017, all promoters of AllTest Biotech legally convened the inaugural meeting and the first shareholders' meeting of the joint stock company, adopted the company's articles of association, and elected the directors for the first board of directors and the non-employee representative supervisors for the first board of supervisors. On November 29, 2017, AllTest Biotech obtained the Business License (Unified Social Credit Code: 91330101685842840Y) issued by the Hangzhou Market Supervision Administration.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hangzhou Jingguan Investment Management Co., Ltd. General Legal Person 1849.26 23.33
2 Hangzhou Qunze Investment Management Co., Ltd. General Legal Person 1502.20 18.95
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 218.73 2.76
4 Hangzhou Saida Investment Partnership (Limited Partnership) General Legal Person 209.29 2.64
5 GTJA Polaris Value Advantage Flexible Allocation Hybrid Securities Investment Fund Class A Fund 71.33 0.90
6 Ningbo Weny Venture Capital Partnership (General Partnership) General Legal Person 70.23 0.89
7 Penghua Hongjia Flexible Allocation Hybrid Securities Investment Fund Class A Fund 44.95 0.57
8 Penghua Anqing Hybrid Securities Investment Fund Class A Fund 6.28 0.08
9 Penghua Anhe Hybrid Securities Investment Fund Class A Fund 5.54 0.07
10 Penghua Zunhui 18-month Regular Open Hybrid Securities Investment Fund Class A Fund 4.39 0.06

5. Concept Sectors

  • Gene Concept
  • Helicobacter Pylori
  • Assisted Reproduction
  • Hepatitis Concept
  • Pet Economy
  • Margin Trading & Securities Lending
  • Blue-chip Stocks
  • Below IPO Price
  • Overseas Business
  • CSI Dividend
  • STAR 200
  • SSE 580

Remarks

  • Data update date: 2025-11-01
  • Data source: Public Market Information